On Friday, the New England Health Institute (NEHI), outlined six “Priorities for Action” to help steer the solution to better medication adherence in the US.
By
Clark Herman
| Published: August 1, 2013
On Friday, the New England Health Institute (NEHI), outlined six “Priorities for Action” to help steer the solution to better medication adherence in the US. These priorities signal public and private policymakers alike to improve the way patients take their medication.
In 2009, NEHI published research which found that people with poor medication adherence, either by not taking their medication accordingly or not at all, cost the US health care system $290 billion annually. In addition to this research, the Congressional Budget Office published its own study describing the beneficial impact of adherence to therapy; with a projected 5% increase from exposure of Medicare to cover drugs would lead to a 1% decrease in the programs medical and hospital spending.
NEHI’s new report, which resulted from a series of roundtables on adherence in 2012, focuses on the following six points in developing a comprehensive, system-wide solution:
For more information, visit NEHI’s website: http://www.nehi.net
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.